Breaking News Instant updates and real-time market news.

AMRS

Amyris

$4.07

-0.25 (-5.79%)

16:45
08/22/19
08/22
16:45
08/22/19
16:45

Amyris receives deficiency notification from Nasdaq

Amyris reported that it has received a standard notice from Nasdaq stating that, as a result of not having timely filed its quarterly report on Form 10-Q for the quarter ended June 30, 2019, and because it remains delinquent in filing its annual report on Form 10-K for the year ended December 31, 2018 and its quarterly report on Form 10-Q for the quarter ended March 31, 2019, it is not in compliance with Nasdaq Listing Rule 5250c1, which requires timely filing of periodic financial reports with the Securities and Exchange Commission.

  • 27

    Aug

AMRS Amyris
$4.07

-0.25 (-5.79%)

11/14/18
HCWC
11/14/18
NO CHANGE
Target $11
HCWC
Buy
Amyris price target lowered to $11 from $15 at H.C. Wainwright
H.C. Wainwright analyst Amit Dayal lowered his price target for Amyris to $11 to reflect a more conservative stance on forward projections, including removing around $40M of anticipated annual Vitamin E royalty revenues, following the company's revenue miss in Q3. The analyst, however, keeps a Buy rating on the shares.
12/07/18
HCWC
12/07/18
NO CHANGE
HCWC
Amyris financing removes 'important overhang,' says H.C. Wainwright
H.C. Wainwright analyst Amit Dayal reiterated a Buy rating and $11 price target on Amyris, noting that the company announced it has entered into definitive agreements for the sale of $60M of unsecured convertible senior notes, in a private placement with two investors. Dayal said this financing removes an "important overhang" for the company, and believes that Amyris is now positioned to focus on execution during 2019. The analyst added that he is looking forward to more information from the company during the last three weeks of this year, including the announcement of a Chinese licensing agreement.
12/31/18
HCWC
12/31/18
NO CHANGE
Target $11
HCWC
Buy
Amyris news today a 'significant near-term milestone,' says H.C. Wainwright
H.C. Wainwright analyst Amit Dayal maintains a Buy rating on Amyris with an $11 price target after the company entered into a long-term agreement with Xinfu for an upfront payment of $50M and an additional long-term annual share upside based on an existing nutritional product royalty arrangement. Amyris is capitalizing on its relationship with Xinfu to monetize a portion of the long-term royalty opportunity upfront, which should lower quarterly volatility from this "high-margin" revenue stream while continuing to benefit from future royalty payments, Dayal tells investors in a research note. He thinks today's news should be viewed as a "timely delivery of a significant near-term milestone by the management team."
02/05/19
HCWC
02/05/19
NO CHANGE
Target $11
HCWC
Buy
H.C. Wainwright reiterates $11 target on Amyris after $255M cannabinoid deal
Amyris this morning announced a $255M collaboration agreement, its largest yet, with an unnamed partner, for cannabinoid development and licensing, H.C. Wainwright analyst Amit Dayal tells investors in a research note. The analyst reiterates a Buy rating on the shares with an $11 price target. The stock in morning trading is up 42%, or $1.33, to $4.49. Dayal believes the agreement calls for several molecules that will be targeting multiple products and end markets, with the first commercial production taking place in 18-24 months. He thinks the early applications are targeting opportunities in the skin care and beverage markets. Further, with an executed binding term sheet in place leading to the announcement, Dayal sees a "high probability" of the deal closing within the expected timeline. And since the non-psychoactive cannabidiol based molecules developed using Amyris' fermentation technology are likely to bypass the psychoactive tetrahydrocannabinol molecule pathway, the regulatory approval process "should not run afoul of the federal THC related restrictions," the analyst writes. He views today's announcement as an "important signal about the scalability" of Amyris' technology platform to enter large new markets very quickly. The analyst also believes the development timeline is "realistic given that product development has been accelerating at the company."

TODAY'S FREE FLY STORIES

CNHI

CNH Industrial

$11.19

-0.01 (-0.09%)

12:21
09/16/19
09/16
12:21
09/16/19
12:21
Periodicals
Elliott builds stake in CNH, sees value in breakup, Bloomberg reports »

Paul Singer's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHE

Chemed

$421.82

0.32 (0.08%)

12:19
09/16/19
09/16
12:19
09/16/19
12:19
Hot Stocks
Chemed subsidiary acquires franchise operater for $120M »

Roto-Rooter Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 19

    Nov

  • 20

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
09/16/19
09/16
12:17
09/16/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
09/16/19
09/16
12:16
09/16/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADNT

Adient

$24.79

-0.32 (-1.27%)

12:15
09/16/19
09/16
12:15
09/16/19
12:15
Options
Adient put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

HLUYY

Lundbeck

$0.00

(0.00%)

, ALDR

Alder Biopharmaceuticals

$18.43

8.38 (83.38%)

12:14
09/16/19
09/16
12:14
09/16/19
12:14
Downgrade
BMO downgrades Alder after buyout, sees another bidder as unlikely »

BMO Capital analyst…

HLUYY

Lundbeck

$0.00

(0.00%)

ALDR

Alder Biopharmaceuticals

$18.43

8.38 (83.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 21

    Feb

GM

General Motors

$37.62

-1.21 (-3.12%)

, XOM

Exxon Mobil

$73.74

1.11 (1.53%)

12:08
09/16/19
09/16
12:08
09/16/19
12:08
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks are lower and oil…

GM

General Motors

$37.62

-1.21 (-3.12%)

XOM

Exxon Mobil

$73.74

1.11 (1.53%)

CVX

Chevron

$123.81

2.35 (1.93%)

WLL

Whiting Petroleum

$10.42

2.885 (38.31%)

DNR

Denbury Resources

$1.54

0.33 (27.27%)

XOG

Extraction Oil & Gas

$3.95

0.725 (22.52%)

CDEV

Centennial Resource Development

$5.62

1.21 (27.44%)

ALDR

Alder Biopharmaceuticals

$18.42

8.37 (83.28%)

SEMG

SemGroup

$16.79

6.51 (63.33%)

ET

Energy Transfer LP

$13.52

-0.49 (-3.50%)

NEWR

New Relic

$54.62

-3.72 (-6.38%)

LL

Lumber Liquidators

$9.12

-0.65 (-6.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 08

    Oct

  • 09

    Oct

  • 07

    Nov

  • 13

    Nov

  • 21

    Feb

MGM

MGM Resorts

$28.82

-0.22 (-0.76%)

, BX

Blackstone

$53.49

-0.06 (-0.11%)

12:07
09/16/19
09/16
12:07
09/16/19
12:07
Periodicals
Blackstone in talks to buy Bellagio and MGM Grand, Bloomberg reports »

Blackstone Group (BX) is…

MGM

MGM Resorts

$28.82

-0.22 (-0.76%)

BX

Blackstone

$53.49

-0.06 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 26

    Sep

CEO

Cnooc

$162.07

10.57 (6.98%)

12:05
09/16/19
09/16
12:05
09/16/19
12:05
Upgrade
Cnooc rating change  »

Cnooc upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$41.87

0.06 (0.14%)

12:05
09/16/19
09/16
12:05
09/16/19
12:05
Conference/Events
Boston Scientific participates in a conference call with SVB Leerink »

Conference call with SVP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 13

    Nov

NEWR

New Relic

$53.86

-4.48 (-7.68%)

12:01
09/16/19
09/16
12:01
09/16/19
12:01
Recommendations
New Relic analyst commentary  »

New Relic price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$16.91

-1.94 (-10.29%)

12:00
09/16/19
09/16
12:00
09/16/19
12:00
Hot Stocks
Direxion Daily Junior Gold Miners Index Bear 3x Shares falls -10.2% »

Direxion Daily Junior…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCO

Scor ADR

$13.52

-3.825 (-22.06%)

12:00
09/16/19
09/16
12:00
09/16/19
12:00
Hot Stocks
Scor ADR falls -21.8% »

Scor ADR is down -21.8%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWT

Britannia Bulk

$4.37

-2.11 (-32.56%)

12:00
09/16/19
09/16
12:00
09/16/19
12:00
Hot Stocks
Britannia Bulk falls -32.8% »

Britannia Bulk is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRC

California Resources

$14.50

2.68 (22.67%)

12:00
09/16/19
09/16
12:00
09/16/19
12:00
Hot Stocks
California Resources rises 22.6% »

California Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$10.27

2.74 (36.39%)

12:00
09/16/19
09/16
12:00
09/16/19
12:00
Hot Stocks
Whiting Petroleum rises 36.5% »

Whiting Petroleum is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Oct

  • 09

    Oct

HYG

iShares iBoxx $ High Yield Corporate Bond

$87.31

0.16 (0.18%)

12:00
09/16/19
09/16
12:00
09/16/19
12:00
Options
Puts lead calls 15:1 in High Yield Bond ETF on vertical spread buyer »

Puts lead calls 15:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEMG

SemGroup

$16.82

6.54 (63.62%)

12:00
09/16/19
09/16
12:00
09/16/19
12:00
Hot Stocks
SemGroup rises 63.6% »

SemGroup is up 63.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:00
09/16/19
09/16
12:00
09/16/19
12:00
General news
Treasury's $87 B 3- and 6-month bill auction results were generally below average »

Treasury's $87 B 3-…

VLGEA

Village Super Market

$26.70

0.05 (0.19%)

11:53
09/16/19
09/16
11:53
09/16/19
11:53
Hot Stocks
Village Super Market board of directors authorizes $5M share repurchase program »

The company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOT

Total

$52.62

0.875 (1.69%)

11:51
09/16/19
09/16
11:51
09/16/19
11:51
Upgrade
Total rating change  »

Total upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

OCN

Ocwen

$2.00

0.01 (0.50%)

11:50
09/16/19
09/16
11:50
09/16/19
11:50
Options
April call buyer in $2 stock Ocwen Financial »

April call buyer in $2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDR

Alder Biopharmaceuticals

$18.42

8.37 (83.28%)

11:47
09/16/19
09/16
11:47
09/16/19
11:47
Downgrade
Alder Biopharmaceuticals rating change  »

Alder Biopharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 21

    Feb

MET

MetLife

$47.56

-0.8 (-1.65%)

11:40
09/16/19
09/16
11:40
09/16/19
11:40
Options
Large call seller appears to average up on short calls in MetLife »

Large call seller appears…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

EQNR

Equinor

$20.16

0.72 (3.70%)

11:39
09/16/19
09/16
11:39
09/16/19
11:39
Upgrade
Equinor rating change  »

Equinor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.